In 2026, oncology drug development in Asia may move away from the historical maximum tolerated dose (MTD) paradigm towar...
2025 was the year when China’s stratospheric rise on the global biotech stage continued. According to a report fro...
When Najat Khan steps into her new role as CEO and President of Recursion, she inherits more than a celebrated...
Puerto Rico’s transformation into a powerhouse of advanced biopharmaceutical manufacturing is gaining new momentum...
Artificial intelligence is rewriting the language of pathology, and Pictor Labs stands firmly at t...
API China, the China International Pharmaceutical Ingredients, Intermediates, Packaging and Equipment Trade Fair, offici...
In a special conversation with BioSpectrum Asia, Yang Huang, Head of China Healthcare Research at J.P. Morgan, shares sh...
Vietnam’s pharmaceutical market is expanding rapidly. According to Fitch Solutions, it was valued at $6 billion in...
A Chinese man who lost all four limbs in a high-voltage electrical accident 13 years ago can now play chess and racing g...
The vaccine landscape in Asia-Pacific is undergoing significant transformation and growth. While public-sector programme...
How does the Oncomine Dx Express Test Multi-CDx System improve on your earlier Oncomine Dx Target Test, and what impact ...
Ageing — the elusive truth of life, has long been debated by philosophers and tapped by the cosmetic industry. Mor...
Global demand for cell and gene therapies is rising, with the Asia-Pacific (APAC) region playing an increasingly signifi...
To effectively address the growing needs and evolving structure of this sector, DHL is investing €500 million into ...
In an exclusive conversation with BioSpectrum Asia, Christopher Ong, Managing Director of DHL Express Singapore, shares ...
Sharing his perspectives with BioSpectrum Asia, Narayana Rao Rapolu, Senior Vice President, Global Bioprocessing...
Australian biotech is known for its cutting-edge research, robust clinical trial activity, and favourable R&D infras...
Global interest in radiopharmaceuticals has surged in recent years, driven by a string of high-profile deals and rising ...
Day 2 of BIO Asia–Taiwan 2025 unfolded with palpable energy and a heightened sense of purpose as stakeholders from...
Cell and gene therapies are reshaping the landscape of modern medicine—but bringing these transformative treatment...
BioSpectrum Asia spoke to Dr Peter Fedichev, CEO of Gero, who explains how ProtoBind-Diff is transforming drug discovery...
It’s universally acknowledged that Asia-Pacific (APAC) is a hotbed for clinical trials, with multiple reports conf...
As Hong Kong accelerates its transformation into a global biotech and MedTech powerhouse, BioSpectrum ...
Ella Woger-Nieves, Chief Executive Officer of Invest Puerto Rico, spoke to BioSpectrum Asia and BioSpectrum Indi...
As the field shifts toward safer and more efficient gene delivery methods, PlasmidFactory’s proprietary technology...
